| Nov 14 |
Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024
|
| Nov 14 |
Alumis reports Q3 results
|
| Nov 13 |
Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements
|
| Nov 4 |
Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference
|
| Oct 9 |
Jim Cramer Says He's Buying 'Some Target,' But Dismisses SoundHound AI As 'Meme Stock'
|
| Oct 4 |
Alumis: Could This Broken Immunology IPO Become The Next Amgen?
|
| Sep 27 |
Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study
|
| Sep 16 |
Alumis: Recent IPO With Differentiated Data In Autoimmune Diseases
|
| Sep 3 |
Alumis to Participate in Upcoming September Investor Conferences
|
| Aug 14 |
Alumis reports Q2 results
|
